Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy

Author(s): Josephine M. Forbes, Vicki Thallas-Bonke, Mark E. Cooper and Merlin C. Thomas

Volume 10, Issue 27, 2004

Page: [3361 - 3372] Pages: 12

DOI: 10.2174/1381612043383151

Price: $65


Advanced glycation end products (AGEs) in diabetic nephropathy have been extensively researched over the last decade and are now firmly established as major players in this disease. The enigma remains the search for the ideal AGE inhibition therapy, which is a great challenge in the context of the structural diversity inherent to AGE chemistry. Certainly, there is a requirement to standardize measurements of circulating and tissue levels of AGEs and to characterize the pathogenic potential of specific AGE moieties. In order to develop more effective, targeted approaches to combat diabetic nephropathy, the mechanisms of action of selective AGE inhibitors and the inter-relationships of advanced glycation with other pathogenic pathways must be addressed.

Keywords: advanced glycation end products, diabetes, diabetic nephropathy, age inhibitor, cross-link breaker, cml, pentosidine, rage

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy